Weiming Li

636 total citations
36 papers, 479 citations indexed

About

Weiming Li is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Weiming Li has authored 36 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 17 papers in Genetics and 7 papers in Oncology. Recurrent topics in Weiming Li's work include Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Mesenchymal stem cell research (7 papers). Weiming Li is often cited by papers focused on Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Mesenchymal stem cell research (7 papers). Weiming Li collaborates with scholars based in China, United States and Canada. Weiming Li's co-authors include Ping Zou, Yong You, Zhigang Zhao, Hongping Zhu, Zhihui Jiang, Qiubai Li, Zhichao Chen, Zhenling Wang, Li Sun and Wen Xu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Weiming Li

32 papers receiving 468 citations

Peers

Weiming Li

GENET

HEMAT

IMMUN

CSE

J Chen China

Huafeng Wang China

Qiguo Zhang China

Jae-Il Choi South Korea

Hongyan Kang China

Myung-Hoon Lee South Korea

Dan Liang China

Zhenyan Li China

Jie Zou China

C. Gray United States

J Chen China

Weiming Li

42 ×0.3

GENET

155 ×1.2

HEMAT

207 ×1.7

20 ×0.3

IMMUN

37 ×0.6

CSE

Citations per year, relative to Weiming Li Weiming Li (= 1×) peers J Chen

Countries citing papers authored by Weiming Li

Since Specialization

Citations

This map shows the geographic impact of Weiming Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiming Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiming Li more than expected).

Fields of papers citing papers by Weiming Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiming Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiming Li. The network helps show where Weiming Li may publish in the future.

Co-authorship network of co-authors of Weiming Li

This figure shows the co-authorship network connecting the top 25 collaborators of Weiming Li. A scholar is included among the top collaborators of Weiming Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiming Li. Weiming Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yuan, Mengyao, Yanli Zhang, Bingcheng Liu, et al.. (2025). Treatment‐free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure. British Journal of Haematology. 207(4). 1408–1415. 1 indexed citations

Li, Weiming, et al.. (2025). Eco-compensation policy to promote households’ behavior for comprehensive utilization of crop straw: Do the positive effects last?. Sustainable Futures. 9. 100505–100505. 1 indexed citations

Cheng, Fang, et al.. (2025). Dasatinib Dose Optimization Based on Therapeutic Drug Monitoring in Patients with Chronic-Phase Chronic Myeloid Leukemia. Drug Design Development and Therapy. Volume 19. 4311–4320. 1 indexed citations

Lei, Yutian, Xiaoli Zhao, Chun Qiao, et al.. (2025). Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study. Therapeutic Advances in Medical Oncology. 17. 22780641–22780641.

Yu, Lu, Weiming Li, Na Xu, et al.. (2024). Patient‐reported outcomes in adults with tyrosine kinase inhibitor‐resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer. 131(1). e35652–e35652. 1 indexed citations

Cheng, Fang, et al.. (2024). Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia. International Immunopharmacology. 133. 112090–112090. 2 indexed citations

Cheng, Fang, et al.. (2023). Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia. International Immunopharmacology. 124(Pt A). 110847–110847. 3 indexed citations

Cheng, Fang, Qiang Li, Jinglin Wang, et al.. (2022). HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia. Disease Markers. 2022. 1–22. 8 indexed citations

Zhou, Shu, Weiming Li, Yi Xiao, et al.. (2020). A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. Leukemia. 35(1). 119–129. 21 indexed citations

10.

He, Yuanyuan, et al.. (2019). Northeast Chinese lamprey (Lethenteron morii) MyD88: Identification, expression, and functional characterization. Fish & Shellfish Immunology. 94. 539–547. 7 indexed citations

11.

Li, Min, Zhixian Jin, Wei Zhang, et al.. (2019). Comparison of chemical stability and corrosion resistance of group IV metal oxide films formed by thermal and plasma-enhanced atomic layer deposition. Scientific Reports. 9(1). 10438–10438. 50 indexed citations

12.

Zhao, Zhigang, Zhenling Wang, Qiubai Li, et al.. (2012). The Different Immunoregulatory Functions of Mesenchymal Stem Cells in Patients with Low-Risk or High-Risk Myelodysplastic Syndromes. PLoS ONE. 7(9). e45675–e45675. 42 indexed citations

13.

Zhao, Zhigang, Wen Xu, Li Sun, et al.. (2011). The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia. European Journal of Cancer. 48(12). 1884–1895. 28 indexed citations

14.

Zhang, Xinli, Bruno Péault, Weiwei Chen, et al.. (2011). The Nell-1 Growth Factor Stimulates Bone Formation by Purified Human Perivascular Cells. Tissue Engineering Part A. 17(19-20). 2497–2509. 54 indexed citations

15.

Hao, Jinjin, Weiming Li, Ping Zou, et al.. (2009). Expressions of tissue factor and tissue factor pathway inhibitor in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Huazhong University of Science and Technology [Medical Sciences]. 29(6). 697–700. 1 indexed citations

16.

Zhao, Zhigang, Weiming Li, Zhichao Chen, Yong You, & Ping Zou. (2008). Hematopoiesis Capacity, Immunomodulatory Effect andEx VivoExpansion Potential of Mesenchymal Stem Cells Are Not Impaired by Cryopreservation. Cancer Investigation. 26(4). 391–400. 9 indexed citations

17.

Han, Liping, et al.. (2008). Calcium‐sensing receptors induce apoptosis in cultured neonatal rat ventricular cardiomyocytes during simulated ischemia/reperfusion. Cell Biology International. 32(7). 792–800. 34 indexed citations

18.

Li, Quan, Jian Zhang, Ping Zou, & Weiming Li. (2008). Proteinase-activated receptor-1 mediates allogeneic CD8+ T cell-induced apoptosis of vascular endothelial cells. Medical Oncology. 26(4). 379–385. 4 indexed citations

19.

Zhao, Zhigang, Weiming Li, Zhichao Chen, Yong You, & Ping Zou. (2008). Immunosuppressive Properties of Mesenchymal Stem Cells Derived from Bone Marrow of Patients with Chronic Myeloid Leukemia. Immunological Investigations. 37(7). 726–739. 20 indexed citations

20.

Liu, Lingbo, et al.. (2007). hMRE11 plays an important role in U937 cellular response to DNA double-strand breaks following etoposide.. PubMed. 15(1). 10–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact